Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine, the …
Background Over the past 2 decades, the use of intravenous ketamine infusions as a
treatment for chronic pain has increased dramatically, with wide variation in patient …
treatment for chronic pain has increased dramatically, with wide variation in patient …
Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review
N Schimmers, JJ Breeksema, SY Smith-Apeldoorn… - …, 2022 - Springer
Background Terminally ill patients may experience existential distress, depression, or
anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or …
anxiety, limiting quality of life in the final stage. Existing psychotherapeutic or …
Targeting glutamate signalling in depression: progress and prospects
Major depressive disorder (MDD) is severely disabling, and current treatments have limited
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …
efficacy. The glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist ketamine was …
[HTML][HTML] Pathophysiology and current drug treatments for post-stroke depression: a review
Post-stroke depression (PSD) is a biopsychosocial disorder that affects individuals who
have suffered a stroke at any point. PSD has a 20 to 60 percent reported prevalence among …
have suffered a stroke at any point. PSD has a 20 to 60 percent reported prevalence among …
[HTML][HTML] Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial
Ketamine has rapid-onset antidepressant activity in patients with treatment-resistant major
depression (TRD). The safety and tolerability of racemic ketamine may be improved if given …
depression (TRD). The safety and tolerability of racemic ketamine may be improved if given …
Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight
We present a review and analysis of the ethical considerations in off-label ketamine use for
severe, treatment-resistant depression. The analysis of ethical considerations is …
severe, treatment-resistant depression. The analysis of ethical considerations is …
Oral ketamine for depression: an updated systematic review
S Meshkat, S Haikazian, JD Di Vincenzo… - The World Journal of …, 2023 - Taylor & Francis
Objectives: Ketamine is a glutamate N-methyl-D-aspartate receptor antagonist that can be
used to treat major depressive disorder by single or repeated infusions. However, the …
used to treat major depressive disorder by single or repeated infusions. However, the …
Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study
Y Domany, M Bleich-Cohen, R Tarrasch… - The British Journal of …, 2019 - cambridge.org
BackgroundKetamine has been demonstrated to improve depressive symptoms.
AimsEvaluation of efficacy, safety and feasibility of repeated oral ketamine for out-patients …
AimsEvaluation of efficacy, safety and feasibility of repeated oral ketamine for out-patients …
[HTML][HTML] Lower urinary tract symptoms in depression: a review
DJ Anderson, A Aucoin, CR Toups… - Health psychology …, 2023 - ncbi.nlm.nih.gov
Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …
population as patients age with approximately a third of individuals experiencing LUTS …
Administration of ketamine for unipolar and bipolar depression
C Kraus, U Rabl, T Vanicek, L Carlberg… - … journal of psychiatry …, 2017 - Taylor & Francis
Objective: Clinical trials demonstrated that ketamine exhibits rapid antidepressant efficacy
when administered in subanaesthetic dosages. We reviewed currently available literature …
when administered in subanaesthetic dosages. We reviewed currently available literature …